Heuson J C, Engelsman E, Blonk-Van Der Wijst J, Maass H, Drochmans A, Michel J, Nowakowski H, Gorins A
Br Med J. 1975 Jun 28;2(5973):711-3. doi: 10.1136/bmj.2.5973.711.
A randomized clinical trial of nafoxidine, a non-steroidal oestrogen antagonist, and ethinyloestradiol in postmenopausal patients with advanced breast cancer produced objective remissions in 31% of 49 women receiving nafoxidine and in 14% of 49 receiving ethinyloestradiol. The differences in remission rates was almost significant (0.05 less than P less than 0.10). Life-threatening complications were more frequent with ethinyloestradiol than with nafoxidine but the latter produced specific toxic reactions on skin and hair that may limit its practical usefulness. Synthetic oestrogen antagonists may occupy a privileged place in the treatment of breast cancer, and other representatives of this new class of compounds should be accurately assessed in randomized clinical trials.
一项关于非甾体雌激素拮抗剂萘福昔定与炔雌醇在绝经后晚期乳腺癌患者中的随机临床试验显示，49名接受萘福昔定治疗的女性中有31%出现客观缓解，49名接受炔雌醇治疗的女性中有14%出现客观缓解。缓解率的差异几乎具有显著性（0.05＜P＜0.10）。与萘福昔定相比，炔雌醇导致的危及生命的并发症更为常见，但后者会对皮肤和头发产生特定的毒性反应，这可能会限制其实际应用。合成雌激素拮抗剂在乳腺癌治疗中可能占据特殊地位，这类新型化合物的其他代表物应在随机临床试验中进行准确评估。
